X0306 4/A 2017-11-13 2017-11-15 0 0001367644 Emergent BioSolutions Inc. EBS 0001380185 El-Hibri Fuad 400 PROFESSIONAL DRIVE, SUITE 400 GAITHERSBURG MD 20879 1 1 1 0 Chairman Common Stock 2017-11-13 4 M 0 20000 22.03 A 1550216 D Common Stock 2017-11-13 4 S 0 20000 40.69 D 1530216 D Common Stock 2017-11-14 4 M 0 20000 22.03 A 1550216 D Common Stock 2017-11-14 4 S 0 20000 40.05 D 1530216 D Common Stock 4344250 I By Intervac, L.L.C. Common Stock 1524155 I By Biovac, L.L.C. Employee Stock Options (Right to Buy) 22.03 2017-11-13 4 M 0 20000 0.00 D 2018-03-14 Common Stock 20000 67983 D Employee Stock Options (Right to Buy) 22.03 2017-11-14 4 M 0 20000 0.00 D 2018-03-14 Common Stock 20000 47983 D All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. The selling price of $40.69 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $40.26 to $40.98, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. The selling price of $40.05 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $39.81 to $40.55, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein. Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein. The options vested in three equal installments on March 14, 2012, March 14, 2013 and March 14, 2014. /s/ Carl A. Valenstein, attorney-in-fact 2017-11-17